Breaking News

Cedarburg Hauser Appoints Process Development Director

By Kristin Brooks | February 11, 2014

Tretyakov to lead process and analytical development groups

Alex Tretyakov, Ph.D. has been appointed director of process development at Cedarburg Hauser Pharmaceuticals (CHP). Dr. Tretyakov will lead the company's process and analytical development groups, and will join chief scientific officer John Lynch, in providing technical insight into customer projects.
 
Most recently, Dr. Tretyakov served as vice president of R&D at PCI Synthesis and Cambridge Major Laboratories.
 
"In his 25-plus years of industry experience Alex has demonstrated a real ability to streamline processes and drive growth via scientific excellence," said CHP chief executive officer Tony Laughrey. "We are counting on Dr. Tretyakov to help accelerate Cedarburg Hauser's growth and are excited to have him on board."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments